Lung cancer continues to contribute to the highest percentage of cancer-related deaths worldwide. Advancements in the treatment of non-small cell lung cancer like immune checkpoint inhibitors have dramatically improved survival and long-term disease response, even in curative and perioperative settings. Unfortunately, resistance develops either as an initial response to treatment or more commonly as a progression after the initial response. Several modalities have been utilized to combat this. This review will focus on the various combination treatments with immune checkpoint inhibitors including the addition of chemotherapy, various immunotherapies, radiation, antibody–drug conjugates, bispecific antibodies, neoantigen vaccines, and tumor-infiltrating lymphocytes. We discuss the status of these agents when used in combination with immune checkpoint inhibitors with an emphasis on lung cancer. The early toxicity signals, tolerability, and feasibility of implementation are also reviewed. We conclude with a discussion of the next steps in treatment.
肺癌在全球癌症相关死亡中仍占据最高比例。非小细胞肺癌治疗领域取得的进展，如免疫检查点抑制剂的应用，显著提升了患者的生存率和长期疾病缓解率，甚至在根治性及围手术期治疗中也展现出积极效果。然而，耐药性问题依然存在，既可表现为初始治疗无应答，更常见的是在初始应答后出现疾病进展。目前已有多种策略被用于应对这一挑战。本综述将重点探讨免疫检查点抑制剂与不同治疗模式的联合应用，包括联合化疗、多种免疫疗法、放疗、抗体偶联药物、双特异性抗体、新抗原疫苗以及肿瘤浸润淋巴细胞疗法。我们将重点围绕肺癌领域，系统阐述这些联合治疗方案的研究现状，并对其早期毒性信号、耐受性及临床实施可行性进行评述。最后，本文将对下一步治疗方向进行展望。
肿瘤(癌症)患者之家